(CercleFinance.com) – The New York Stock Exchange continues its progression with an increase of 0.3% on the S&P500 and 0.4% on the Dow Jones, the day after a euphoric session by Nvidia, a real locomotive for American markets for months.
‘In a market where performance is very concentrated, Nvidia’s excellent results are certainly much more important for the short-term trajectory of the stock market than any statistics or central bank decision,’ says Pictet. AM.
Indeed, the title of the processor designer jumped more than 16% on Thursday, dragging in its wake the equity indices as a whole, starting with the Nasdaq Composite with a strong technological component, which gained almost 3%.
This last session of the week could, however, see buyers take a break after these vigorous gains in the stock markets (+2.1% on the S&P500), and while no macroeconomic data is expected this Friday.
In stock news, Warner Bros. Discovery unveiled Thursday evening a net loss of $400 million for the last three months of 2023, divided by five in annual comparison, but adjusted EBITDA down from 5% to 2, 47 billion.
For its part, the accounting and tax software publisher Intuit published, for its second quarter 2023-24, an adjusted EPS up 20% to 2.63 dollars and an adjusted operating profit up 17 % to a billion all round.
Bristol Myers Squibb announces the success of its takeover bid worth more than four billion dollars for the RayzeBio group, as well as a favorable opinion from the CHMP of the European Medicines Agency for its Reblozyl in transfusional anemia.
Merck today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has given a positive opinion recommending the approval of Keytruda + platinum-based chemotherapy as neoadjuvant therapy, or Keytruda as adjuvant therapy in patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence.
Copyright (c) 2024 CercleFinance.com. All rights reserved.